SIRS-Lab Commences Clinical Trial for PCR-Array-Based Sepsis Test

German molecular diagnostics firm SIRS-Lab this week commenced a 1,000-patient clinical study in its home country to evaluate Vyoo, the company's PCR- and microarray-based molecular test for causative agents of sepsis. Results from the study will support an application for regulatory approval in Europe.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.